Testing a new insulin delivery method for type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new way to give insulin directly into the abdomen (intraperitoneal) for people with type 1 diabetes. It will check how safe and effective a single dose is over 12 hours, using a special procedure to keep blood sugar stable (clamp).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have had type 1 diabetes for at least 12 months.
- You use an insulin pump or multiple daily injections (basal and bolus) and have been on a stable dose for at least 3 months.
- Your average blood sugar (HbA1c) is 8.5% or lower.
- Your body mass index (BMI) is between 18.5 and 30, and you weigh at least 50 kg.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new automated insulin delivery system to help people with type 1 diabetes better manage their blood sugar. It aims to see if the system improves glucose control safely.
This study tests a system that measures blood sugar and automatically adjusts insulin delivery. It is for adults with type 1 diabetes who use insulin injections or a pump.
This early-stage study tests an investigational insulin (HDV-insulin lispro) given by injection, to see how it affects glucose production in the liver and overall blood sugar control. Participation involves dose-response testing and monitoring, which may help guide future diabetes treatment.
This study tests a smart insulin pump system that adjusts automatically during exercise. It aims to make managing blood sugar easier and safer.
This trial tests an oral medication that may help your body respond better to insulin. It's for people with type 1 diabetes who use an automated insulin pump and are willing to take a daily pill for 12 weeks.
This study compares a continuous “under the skin” diabetes medicine (called beinaglutide) with an insulin pump (CSII) in people who were recently diagnosed with type 2 diabetes. It aims to see which approach works better and is safer for controlling blood sugar.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.